NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free VNRX Stock Alerts $0.73 -0.02 (-2.67%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7650-Day Range$0.72▼$1.1952-Week Range$0.55▼$2.10Volume574,128 shsAverage Volume190,957 shsMarket Capitalization$57.44 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get VolitionRx alerts: Email Address VolitionRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside242.5% Upside$2.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.39Based on 9 Articles This WeekInsider TradingSelling Shares$18,000 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 starsMedical Sector801st out of 939 stocksDiagnostic Substances Industry10th out of 13 stocks 3.5 Analyst's Opinion Consensus RatingVolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, VolitionRx has a forecasted upside of 242.5% from its current price of $0.73.Amount of Analyst CoverageVolitionRx has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VNRX. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VNRX. Previous Next 1.5 News and Social Media Coverage News SentimentVolitionRx has a news sentiment score of -0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for VolitionRx this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,000.00 in company stock.Percentage Held by Insiders15.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About VolitionRx Stock (NYSE:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comVolitionRx (NYSE:VNRX) Receives "Overweight" Rating from Cantor FitzgeraldMarch 25, 2024 | msn.comVNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023March 28, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 25, 2024 | prnewswire.comVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business UpdateMarch 22, 2024 | benzinga.comEarnings Outlook For VolitionRXMarch 21, 2024 | prnewswire.comVolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business UpdateMarch 21, 2024 | finanznachrichten.deVolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical OfficerMarch 21, 2024 | americanbankingnews.comVolitionRx (NYSE:VNRX) Trading Down 4.7%March 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 19, 2024 | markets.businessinsider.comVolitionRx Names Andrew Retter Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comVolition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | money.usnews.comVolitionRX LtdFebruary 22, 2024 | benzinga.comVolitionRX Stock (AMEX:VNRX), Short Interest ReportJanuary 2, 2024 | msn.comVolitionRx stock soars after company discloses $13M in milestone paymentsJanuary 2, 2024 | realmoney.thestreet.comVolitionRx milestone payment 'important step forward,' says EF HuttonNovember 17, 2023 | finance.yahoo.comVolition Presents at the 5th Annual Congress of the International Liquid Biopsy SocietyNovember 8, 2023 | proactiveinvestors.comVolitionRx to host Q3 earnings call on November 15October 28, 2023 | markets.businessinsider.comVolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s PerspectiveSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today3/27/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:VNRX CUSIPN/A CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees114Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+236.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,270,000.00 Net Margins-4,557.29% Pretax Margin-5,255.45% Return on Equity-7,185.73% Return on Assets-166.48% Debt Debt-to-Equity Ratio0.56 Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$770,000.00 Price / Sales75.93 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-14.86Miscellaneous Outstanding Shares78,690,000Free Float66,568,000Market Cap$58.47 million OptionableOptionable Beta1.38 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $227.63kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $538.66kMr. Terig Hughes (Age 54)CFO & Treasurer Comp: $338.74kDr. Gaetan Michel Ph.D. (Age 51)Chief Operating Officer Comp: $445.06kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Scott Powell Ph.D. (Age 50)Executive Vice President of Investor Relations Mr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 53)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey CompetitorsImmuCellNASDAQ:ICCCAspira Women's HealthNASDAQ:AWHCardio DiagnosticsNASDAQ:CDIOARCA biopharmaNASDAQ:ABIOOncoCyteNASDAQ:OCXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 87,195 shares on 3/11/2024Ownership: 0.800%Vanguard Group Inc.Bought 87,195 shares on 2/15/2024Ownership: 0.800%Silverberg Bernstein Capital Management LLCBought 147,038 shares on 1/17/2024Ownership: 0.187%Corp Ltd EightSold 20,000 sharesTotal: $18,000.00 ($0.90/share)Salvatore Thomas ButeraBought 10,000 shares on 12/18/2023Total: $8,300.00 ($0.83/share)View All Insider TransactionsView All Institutional Transactions VNRX Stock Analysis - Frequently Asked Questions Should I buy or sell VolitionRx stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks. What is VolitionRx's stock price target for 2024? 1 brokers have issued 12-month price targets for VolitionRx's stock. Their VNRX share price targets range from $2.50 to $2.50. On average, they predict the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 242.5% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts. How have VNRX shares performed in 2024? VolitionRx's stock was trading at $0.7170 at the beginning of 2024. Since then, VNRX shares have increased by 1.8% and is now trading at $0.73. View the best growth stocks for 2024 here. When is VolitionRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VNRX earnings forecast. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) issued its quarterly earnings results on Monday, March, 25th. The company reported ($0.11) earnings per share for the quarter. The company earned $0.24 million during the quarter, compared to analyst estimates of $0.50 million. VolitionRx had a negative trailing twelve-month return on equity of 7,185.73% and a negative net margin of 4,557.29%. Who are VolitionRx's major shareholders? VolitionRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.80%), Vanguard Group Inc. (0.80%), Silverberg Bernstein Capital Management LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cameron John Reynolds, Corp Ltd Eight, Gaetan Michel, Guy Archibald Innes, Jacob Vincent Micallef, Martin Charles Faulkes, Phillip Barnes, Rodney Gerard Rootsaert and Salvatore Thomas Butera. View institutional ownership trends. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VNRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.